Keke Wang

Keke Wang

Auto-generated profile, based on publicly available information

Keke Wang

Université de Toulouse, INRAe/INP Toulouse, Génomique et Biotechnologie des Fruits—UMR990, Castanet-Tolosan, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Nature Plants
Verified
Journal Article
Closed access
PDF file
GHGuojian Hu
Guojian Hu
KWKeke Wang
Keke Wang
BHBaowen HUANG
Baowen HUANG
IMIsabelle Mila
Isabelle Mila
PFPierre Frasse
Pierre Frasse
MBMondher Bouzayen
Mondher Bouzayen

1 October 2018 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
TZTianshun Zhang
Tianshun Zhang
QWQiushi Wang
Qiushi Wang
MFMangaladoss Fredimoses
Mangaladoss Fredimoses
Ge GaoGe Gao
Ge Gao
KWKeke Wang
Keke Wang
ZDZigang Dong
Zigang Dong
Malignant melanoma is an aggressive tumor of the skin and still lacks effective preventive and therapeutic treatments. In melanoma, both the BRAF/MEK/ERK and PI3-K/AKT signaling pathways are constitutively activated through multiple mechanisms, which result in cell-cycle progression and prevention of apoptosis. Therefore, the development of novel strategies for targeting BRAF and PI3K are of utmost importance. In this study, we found that Ashitaba (Angelica keiskei) chalcones, 4-hydroxyderricin (4HD) and xanthoangelol (XAG), suppressed melanoma development by directly targeting both BRAFV600E and PI3K, which blocked the activation of downstream signaling. This led to the induction of G1 phase cell-cycle arrest and apoptosis in melanoma cells. Importantly, 4HD or XAG dramatically attenuated tumor incidence and volume in the BRAF-activated Pten-deficient melanoma mouse model. Our findings suggest that 4HD and XAG are promising chemopreventive or potential therapeutic agents against melanomagenesis that act by targeting both BRAF and PI3K, providing hope for rapid clinical translation. Cancer Prev Res; 11(10); 607–20. ©2018 AACR.

20 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BLBernard Lassègue
Bernard Lassègue
SKSandeep Kumar
Sandeep Kumar
RMRohan Mandavilli
Rohan Mandavilli
KWKeke Wang
Keke Wang
MTMichelle Tsai
Michelle Tsai
KGKathy K. Griendling
Kathy K. Griendling
POLDIP2 is a multifunctional protein whose roles are only partially understood. Our laboratory previously reported physiological studies performed using a mouse gene trap model, which suffered from three limitations: perinatal lethality in homozygotes, constitutivePoldip2inactivation and inadvertent downregulation of the adjacentTmem199gene. To overcome these limitations, we developed a new conditional floxedPoldip2model. The first part of the present study shows that our initial floxed mice were affected by an unexpected mutation, which was not readily detected by Southern blotting and traditional PCR. It consisted of a 305 kb duplication aroundPoldip2with retention of the wild type allele and could be traced back to the original targeted ES cell clone. We offer simple suggestions to rapidly detect similar accidents, which may affect genome editing using both traditional and CRISPR-based methods. In the second part of the present study, correctly targeted floxedPoldip2mice were generated and used to produce a new constitutive knockout line by crossing with a Cre deleter. In contrast to the gene trap model, many homozygous knockout mice were viable, in spite of having no POLDIP2 expression. To further characterize the effects ofPoldip2ablation in the vasculature, RNA-seq and RT-qPCR experiments were performed in constitutive knockout arteries. Results show that POLDIP2 inactivation affects multiple cellular processes and provide new opportunities for future in-depth study of its functions.



3 April 2023
Verified
Other
Open access
Ge GaoGe Gao
Ge Gao
TZTianshun Zhang
Tianshun Zhang
QWQiushi Wang
Qiushi Wang
KRKanamata Reddy
Kanamata Reddy
HCHanyong Chen
Hanyong Chen
ZDZigang Dong
Zigang Dong